Breaking News Instant updates and real-time market news.

PTI

Proteostasis

$2.35

-0.06 (-2.49%)

, APTO

Aptose Biosciences

$1.97

0.02 (1.03%)

17:39
12/11/17
12/11
17:39
12/11/17
17:39

On The Fly: After Hours Movers

HIGHER: Proteostasis (PTI), up 61.7% after it announced "positive" clinical results from its PTI-801 and PTI-808 studies... Aptose Biosciences (APTO), up 6.1% after it said that CG'806 exerts anti-leukemia effects... RCM Technologies (RCMT), up 5.1% after it declared a $1.00 per share special cash dividend and provided Q4 revenue guidance... Comcast (CMCSA), up 1.5% after Reuters reported that the company abandoned its bid for 21st Century Fox (FOX) assets... Boeing (BA), up 1.2% after it raised its quarterly dividend 20% and established an $18B share repurchase authorization... Boston Scientific (BSX), up 1.1% after it received FDA approval for the Vercise Deep Brain Stimulation system. DOWN AFTER EARNINGS: Casey's General Stores (CASY), down 4.3%. ALSO LOWER: Acer Therapeutics (ACER), down 12.1% after it filed to sell common stock... Argenx (ARGX), down 10.1% after it filed to sell $150M in ADSs... Blueprint Medicines (BPMC), down 2.6%... Iron Mountain (IRM), down 1.7% after it filed to sell 14.5M shares of common stock.

PTI

Proteostasis

$2.35

-0.06 (-2.49%)

APTO

Aptose Biosciences

$1.97

0.02 (1.03%)

RCMT

RCM Technologies

$6.90

0.05 (0.73%)

CMCSA

Comcast

$38.44

0.49 (1.29%)

CMCSK

Comcast

FOX

21st Century Fox

$33.27

0.3 (0.91%)

FOXA

21st Century Fox

$33.66

0.36 (1.08%)

BA

Boeing

$283.16

-2.74 (-0.96%)

BSX

Boston Scientific

$25.50

-0.27 (-1.05%)

CASY

Casey's General Stores

$121.25

-3.56 (-2.85%)

ACER

Acer Therapeutics

$14.15

-0.42 (-2.88%)

ARGX

Argenx

$54.47

24.02 (78.88%)

IRM

Iron Mountain

$40.70

0.58 (1.45%)

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 14

    Dec

PTI Proteostasis
$2.35

-0.06 (-2.49%)

08/16/17
LEER
08/16/17
NO CHANGE
Target $9
LEER
Outperform
Proteostasis price target lowered to $9 from $17 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Proteostasis to $9 from $17 but reiterated an Outperform rating on the shares. The analyst notes that competitive developments have raised investor concern about the future of Proteostasis, but believes the company's current market cap of about $60M reflects a worst case scenario that assigns very little if any credit to the company's technology ahead of potentially impactful data in 2H17 and beyond.
APTO Aptose Biosciences
$1.97

0.02 (1.03%)

09/07/17
HCWC
09/07/17
UPGRADE
Target $4
HCWC
Buy
Aptose Biosciences upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis upgraded Aptose Biosciences to Buy and raised his price target for the shares to $4 from $1. Having finalized manufacturing for CG'806 in a timely manner, Aptose can now further solidify its projected timeline for getting the drug into the clinic, Pantginis tells investors in a research note. The analyst increased his projected chance of success for CG'806 to 7% from 5%.
10/23/17
ROTH
10/23/17
INITIATION
Target $5
ROTH
Buy
Aptose Biosciences resumed with a Buy at Roth Capital
Roth Capital analyst Jotin Marango resumed Aptose Biosciences with a Buy rating and $5 price target as he sees fundamental value discounted due to formulation and manufacturing mishaps.
06/08/17
RODM
06/08/17
INITIATION
Target $1
RODM
Neutral
Aptose Biosciences initiated with a Neutral at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Aptose Biosciences with a Neutral rating and $1.00 price target. The analyst sees a lack of meaningful catalysts for the remainder of 2017.
RCMT RCM Technologies
$6.90

0.05 (0.73%)

CMCSA Comcast
$38.44

0.49 (1.29%)

12/11/17
BTIG
12/11/17
NO CHANGE
BTIG
BTIG says Comcast could pay 'significantly' more for Fox assets than Disney
BTIG analyst Richard Greenfield said earlier in a note to investors that he believes Comcast (CMCSA) could pay "significantly more" for the assets that Fox (FOXA) is reportedly looking to sell than could Disney (DIS). He also believes Comcast could have a better chance of securing regulatory approval for a deal if they are willing to spin off all of the regional sports networks that a combined entity would own.
12/07/17
JEFF
12/07/17
NO CHANGE
JEFF
Jefferies sees Disney, not Comcast, as more likely Fox suitor
Amid press reports that suggest Comcast (CMCSA) continues to pursue 21st Century Fox (FOXA) along with Disney (DIS), Jefferies analyst John Janedis says he sees Disney as the more likely suitor given the regulatory concerns with a Comcast deal. The analyst believes Comcast would need to offer a premium to Disney for Fox to compensate for more regulatory risk. However, assuming Comcast has interest in the same assets as Disney, and using the same $66B value for Fox's assets, the analyst estimates the deal would be high-single-digit dilutive to Comcast earnings, versus neutral to Disney due to relative tax rates.
11/22/17
PIPR
11/22/17
NO CHANGE
Target $25
PIPR
Overweight
TiVo ITC win raises odds of Comcast renewal, says Piper Jaffray
Piper Jaffray analyst Michael Olson said the International Trade Commission ruling in favor of TiVo (TIVO) increases the likelihood that a renewal deal with Comcast (CMCSA) will be reached, but he does not have it built into his estimates until early 2018. He maintains an Overweight rating and $25 price target on TiVo shares, which are up nearly 13% to $19.90 in pre-market trading.
11/21/17
JPMS
11/21/17
NO CHANGE
JPMS
Overweight
ITC ruling a 'significant positive' for TiVo, says JPMorgan
The International Trade Commission tonight ruled in favor of TiVo (TIVO) in its final determination against Comcast (CMCSA), finding that the cable company is infringing on two of the six patents in question, JPMorgan analyst Sterling Auty tells investors in a research note. The analyst views the ruling as a "significant positive" for TiVo and a "major step" in both companies working toward final resolution. He estimates a settlement could bring in $90M-$100M of catchup payments and ongoing royalties to TiVo. Auty has an Overweight rating on the shares.
CMCSK Comcast

11/13/17
PIPR
11/13/17
NO CHANGE
PIPR
Overweight
TiVo CEO selection removes one uncertainty, says Piper Jaffray
Piper Jaffray analyst Michael Olson noted that TiVo's (TIVO) newly-named CEO Enrique Rodriguez has a "strong industry background" including experience launching and improving various entertainment platforms. Olson added that the CEO selection removes one uncertainty, but the status of a renewal at Comcast (CMCSA) remains investors' primary focus. He keeps an Overweight rating on TiVo shares.
11/10/17
COWN
11/10/17
NO CHANGE
Target $30
COWN
Outperform
Court win versus Comcast could lift TiVo shares $6, says Cowen
Cowen analyst Robert Stone noted the FTC has extended its target date for completion of the TiVo (TIVO) and Comcast (CMCSA) investigation to November 16. The analyst believes TiVo will prevail and he believes a win could add $6 to its current valuation. Stone also believes Tivo remains significantly undervalued and he reiterated his Outperform rating and $30 price target on TiVo shares.
FOX 21st Century Fox
$33.27

0.3 (0.91%)

11/10/17
BERN
11/10/17
NO CHANGE
Target $101
BERN
Market Perform
Disney deal for Fox wouldn't solve underlying problems, says Bernstein
Bernstein analyst Todd Juenger noted that Disney (DIS) has gone from a situation where reported EPS was going up but its stock price was going down to one where EPS is going down but the stock has been going up a bit driven by M&A speculation. However, he contends that the current round of renewed M&A speculation is happening because underlying fundamentals are "so bad" and even if a deal for Disney to buy Fox (FOXA) assets happens it wouldn't solve the underlying problems. He also thinks the chances of a Disney-Fox deal as currently described are "very low." Juenger maintains a Market Perform rating and $101 price target on Disney shares.
10/30/17
OTRG
10/30/17
UPGRADE
OTRG
Positive
21st Century Fox upgraded to Positive from Mixed at OTR Global
10/06/17
STFL
10/06/17
NO CHANGE
Target $200
STFL
Buy
Netflix 'still the best value' for consumers despite price hike, says Stifel
After Netflix (NFLX) disclosed it is raising subscription prices for the Standard and Premium tiers in the U.S., Stifel analyst Scott Devitt said he expects "similar round number increases" in a number of other markets, noting that the company has also confirmed increases for its top two U.K. plans. The analyst, who noted that Hulu's ad-free option and HBO Now (TWX) remain as expensive or more expensive than Netflix, said its streaming service is "still the best value on the consumer Internet." Devitt keeps a Buy rating and $200 price target on Netflix shares.
FOXA 21st Century Fox
$33.66

0.36 (1.08%)

12/07/17
WELS
12/07/17
NO CHANGE
Target $40
WELS
Outperform
21st Century Fox price target raised to $40 from $34 at Wells Fargo
Wells Fargo analyst Marci Ryvicker raised her price target for 21st Century Fox (FOXA) saying she believes it would be worth as much per share in a Disney (DIS) deal. The analyst reiterates an Outperform rating on 21st Century Fox shares.
12/05/17
PIPR
12/05/17
NO CHANGE
Target $120
PIPR
Overweight
Piper sees potential Fox deal as 'clear positive' for Disney
Piper Jaffray analyst Stan Meyers weighs in on Disney's (DIS) talks with 21st Century Fox (FOXA) to acquire Fox's film and TV studio, its Sky stake, Star India and some U.S. cable networks. A decision is likely by the end of 2017, the analyst points out. A deal would give Disney an opportunity to add to its "rich" intellectual property assets, evolve the Marvel Cinematic Universe, improve leverage with key counterparts and diversify its revenue streams away from the Pay TV ecosystem, Meyers tells investors in a research note. He estimates the deal size to be roughly $44B. The analyst sees the potential transaction as a "clear positive" for Disney. Meyers keeps an Overweight rating on the shares with a $120 price target.
BA Boeing
$283.16

-2.74 (-0.96%)

10/27/17
ARGS
10/27/17
NO CHANGE
ARGS
Boeing price target raised to $290 from $270 at Argus
Argus analyst John Eade raised his price target of Boeing to $290 from $270 and maintained a Buy rating on shares, highlighting the company's Q3 results beating consensus, management raising its FY17 guidance, as well as recently raising the dividend 30%, and noting the stock's strong gain of 22% over the past quarter.
10/26/17
COWN
10/26/17
NO CHANGE
Target $315
COWN
Outperform
Boeing remains a top pick at Cowen following Q3 report
Cowen analyst Cai von Rumohr said Boeing remains his number one pick following its Q3 reports. The analyst said the company is in an extended execution sweet spot, which could boost earnings into 2020. He also sees beat and raise potential from 787 block extensions and said the shares remain cheap relative to cash flow. The analyst reiterated his Outperform rating and $315 price target on Boeing shares.
11/21/17
JEFF
11/21/17
NO CHANGE
Target $312
JEFF
Buy
Boeing free cash flow should drive shares higher, says Jefferies
Jefferies analyst Sheila Kahyaoglu says "robust" demand for commercial aircraft and higher productivity give her increased confidence that Boeing can grow earnings at a low double-digit rate. Improved cash margins could lead to over $21 per share of free cash flow by 2020, Kahyaoglu tells investors in a research note titled "Cash Should Lead the Shares Higher." The analyst raised her price target for Boeing shares to $312 from $300 and keeps a Buy rating on the name. The plane maker closed yesterday up $2.37 to $264.63.
12/07/17
BERN
12/07/17
NO CHANGE
Target $310
BERN
Outperform
Boeing a 'big winner' if tax reform happens, says Bernstein
Bernstein analyst Douglas Harned says Boeing should be a "big winner" if tax reform passes. Unlike many industrials, Boeing should see most tax reform benefits go to the bottom line for the next five years, he adds. The analyst reiterates an Outperform rating and $310 price target on the shares.
BSX Boston Scientific
$25.50

-0.27 (-1.05%)

12/05/17
COWN
12/05/17
NO CHANGE
Target $130
COWN
Outperform
Edwards Lifesciences should be bought ahead of investor day, says Cowen
Cowen analyst Joshua Jennings said he is a buyer of Edwards Lifesciences (EW) ahead of its investor day and Q4 results. He said the delay of Boston Scientific's (BSX) Lotus supports his belief that Edwards' U.S. TAVR franchise will show consistent sequential growth in front of a mid-2019 low-risk approval. He also believes guidance will be conservative. Jennings reiterated his Outperform rating and $130 price target on Edwards Lifesciences shares.
12/08/17
12/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ingersoll-Rand (IR) upgraded to Buy from Neutral at Goldman Sachs with analyst Joseph Ritchie saying the stock is his favorite value idea for 2018. 2. Boston Scientific (BSX) upgraded to Strong Buy from Buy at Needham analyst Mike Matson citing the company's strong product cycle potential to outperform its peers, runway for more margin expansion, conservative consensus views for fiscal 2018, and potential for even more significant upside from the Lotus Edge program being revived. 3. TravelCenters (TA) upgraded to Neutral from Sell at Citi with analyst Alvin Concepcion citing valuation with the shares down 18% since early October. 4. Vantiv (VNTV) upgraded to Buy from Neutral at Buckingham with analyst Christopher Brendler citing reduced expectations following the third quarter results. 5. Perrigo (PRGO) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg citing reflecting improving results, a promising pipeline, efforts to pay down debt, and valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/08/17
NEED
12/08/17
UPGRADE
Target $32
NEED
Strong Buy
Boston Scientific upgraded to Strong Buy at Needham on product cycle and margins
As reported earlier, Needham analyst Mike Matson upgraded Boston Scientific to Strong Buy from Buy with a $32 price target. Matson cites the company's strong product cycle potential to outperform its peers, runway for more margin expansion, conservative consensus views for FY18, and potential for even more significant upside from the Lotus Edge program being revived. In addition, the analyst says Boston Scientific expects to pay off most of its litigation liabilities next year, allowing for more cash to be deployed in M&A or shareholder returns.
12/08/17
NEED
12/08/17
UPGRADE
NEED
Strong Buy
Boston Scientific upgraded to Strong Buy from Buy at Needham
CASY Casey's General Stores
$121.25

-3.56 (-2.85%)

04/27/17
04/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Microsoft (MSFT) initiated with an Outperform at Credit Suisse. 2. Casey's General Stores (CASY) initiated with a Neutral at Goldman Sachs. 3. Sunoco Logistics (SXL) resumed with a Buy at Citi. 4. Peabody Energy (BTU) initiated with a Buy at MKM Partners. 5. Dexcom (DXCM) assumed with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
SIDC
06/06/17
DOWNGRADE
SIDC
Neutral
Casey's General Stores downgraded to Neutral from Buy at Sidoti
Sidoti analyst Anthony Lebiedzinski downgraded Casey's General Store to Neutral and cut its price target to $118 from $130 citing disappointing Q4 results and guidance.
07/19/17
JEFF
07/19/17
NO CHANGE
JEFF
Jefferies lays out stocks 'overly discounting' Amazon risk
Amazon.com's (AMZN) planned purchase of Whole Foods Market (WFM) has further widened the valuation spread between consumer stocks the market views as resistant to the Aamzon threat and those viewed as vulnerable, Jefferies analysts including Andy Barish and Daniel Binder tells investors in a research note. They believe this dynamic has created opportunities. Specifically, the analysts feel shares of Wal-Mart (WMT), Hain Celestial (HAIN), Foot Locker (FL) and Advance Auto Parts (AAP) are "overly discounting" potential risk from Amazon. Jefferies also believes Casey's General Stores (CASY), Lamb Weston (LW), Murphy USA (MUSA), Monster Beverage (MNST), Starbucks (SBUX) and Ulta Beauty (ULTA) are "well insulated" from Amazon disruption.
06/06/17
06/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Casey's General Stores (CASY) downgraded to Neutral from Buy at Sidoti with analyst Anthony Lebiedzinski citing disappointing fourth quarter results and guidance. 2. ArcelorMittal (MT) downgraded to Underperform from Buy at BofA/Merrill with analyst Cedar Ekblom citing lack of stock-specifc catalysts and steel price headwinds. 3. ITT (ITT) downgraded to Neutral from Buy at Goldman Sachs with analyst Joe Ritchie saying he sees limited room for upward revisions to earnings estimates and believes negative sentiment around auto will remain an overhang on the valuation multiple. 4. Omnicom (OMC) downgraded to Neutral from Outperform at Macquarie with analyst Tim Nollen citing likely cyclical moderation ahead that will pressure agency growth rates.5. Interpublic Group (IPG) downgraded to Neutral from Outperform at Macquarie with analyst Tim Nollen citing cyclical moderation ahead that will pressure agency growth rates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACER Acer Therapeutics
$14.15

-0.42 (-2.88%)

ARGX Argenx
$54.47

24.02 (78.88%)

06/12/17
JMPS
06/12/17
INITIATION
JMPS
Outperform
Argenx initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King started coverage of Argenx with a $33 price target and an Outperform rating. He says that the company's technology gives it "profound competitive advantages over other antibody companies." Target $33.
11/16/17
WEDB
11/16/17
NO CHANGE
Target $41
WEDB
Outperform
Argenx price target raised to $41 from $26 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Argenx to $41 from $26 as he incorporates the pemphigus vulgaris market opportunity into his valuation. The analyst reiterates an Outperform rating on the shares.
06/12/17
PIPR
06/12/17
NO CHANGE
Target $32
PIPR
Overweight
Argenx transitioned with an Overweight at Piper Jaffray
Following the company's Nasdaq IPO, Piper Jaffray transitioned coverage of Argenx to analyst Edward Tenthoff with an Overweight rating and $32 price target.
10/24/17
PIPR
10/24/17
NO CHANGE
Target $32
PIPR
Overweight
Argenx drug has differentiated mechanism to treat MG, says Piper Jaffray
After news that the FDA approved an expanded label for Alexion's (ALXN) Soliris to treat generalized Myasthenia Gravis, or gMG, Piper Jaffray analyst Edward Tenthoff said that while this is a significant milestone he still sees room for new therapies. He believes that Argenx's (ARGX) ARGX-113 has a differentiated mechanism to treat MG and notes it is scheduled to report Phase 2 data on the drug in that indication in the first quarter of 2018. Tenthoff reiterates his Overweight rating and $32 price target on Argenx shares, which are down nearly 4% to $19.42 in morning trading.
IRM Iron Mountain
$40.70

0.58 (1.45%)

02/22/17
DBAB
02/22/17
INITIATION
Target $39
DBAB
Hold
Iron Mountain initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Kevin McVeigh started Iron Mountain with a Hold rating and $39 price target.
06/07/17
DBAB
06/07/17
DOWNGRADE
Target $30
DBAB
Sell
Iron Mountain downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Kevin McVeigh downgraded Iron Mountain to Sell and lowered his price target for the shares to $30 from $41. The favorable interest rate environment has provided a selling opportunity in front of "seasonal summer slack," McVeigh tells investors in a research note. The analyst sees a lack of near-term catalysts and prefers to revisit the shares if rates go lower or if internal growth exceeds expectations.
10/18/17
EVER
10/18/17
INITIATION
Target $46
EVER
Outperform
Iron Mountain initiated with an Outperform at Evercore ISI
Evercore ISI analyst initiated Iron Mountain with an Outperform and $46 price target. The analyst said Iron Mountain's dividend yield of 5.5% is one of the highest in large cap REITS and will continue to capture client's storage needs regardless if its is via paper records or digital needs.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.